The duration of untreated depression is associated with a poor treatment response
Hjerrild, S.; Videbech, P.
Ugeskrift for Laeger 176(5)
2014
ISSN/ISBN: 1603-6824 PMID: 25096008 Document Number: 676430
According to clinical lore the duration of untreated depression is associated with a poor treatment response. This is in accordance with the kindling hypothesis of depression. It is an important subject, since the duration of untreated depression is a potentially modifiable risk factor. Despite this, relatively few studies addressing the problem exist. While an association between the duration of untreated depression and treatment response generally is found, the uncontrolled and often retrospective nature of these studies makes it difficult to ascertain causality.
Document emailed within 1 workday
Related Documents
Kober, G.; Mikludy, R.; Veidt, J.; Kaltenbach, M. 1982: Dose-response relationship and duration of action of acebutolol / investigations on heart rate behaviour and ischemic ST-segment depression Arzneimittel-Forschung 32(8): 835-839Hautzinger, M. 1984: Age at disease onset, duration and recurrence of untreated depressive episodes Der Nervenarzt 55(5): 275
Cechnicki, A.; Hanuszkiewicz, I.; Polczyk, R.; Bielańska, A. 2010: The prospective assessment of the influence of duration of untreated psychosis (DUP) on the course of schizophrenia Psychiatria Polska 44(3): 381-394
Dunn, C.G.; Quinlan, D. 1978: Indicators of E.C.T. response and non-response in the treatment of depression Journal of Clinical Psychiatry 39(7): 620-622
Tolis, G.; Cruess, S.; Goldstein, M.; Friesen, H.G.; Rochefort, J.G. 1974: Survival and growth in a woman with untreated hypothalamic panhypopituitarism of 21 years' duration Canadian Medical Association Journal 111(6): 553-556
Fresán, A.; Apiquian, R.; Ulloa, R.E.; Loyzaga, C.; Nicolini, H.; Gómez, L. 2003: Premorbid functioning by gender and its relationship with duration of untreated psychosis in first psychotic episode Actas Espanolas de Psiquiatria 31(2): 53-58
Bunupuradah, T.; Puthanakit, T.; Kosalaraksa, P.; Kerr, S.J.; Kariminia, A.; Hansudewechakul, R.; Kanjanavanit, S.; Ngampiyaskul, C.; Wongsawat, J.; Luesomboon, W.; Chuenyam, T.; Vonthanak, S.; Vun, M.Chhi.; Vibol, U.; Vannary, B.; Ruxrungtham, K.; Ananworanich, J.; Ruxrungtham, K.; Ananworanich, J.; Puthanakit, T.; Pancharoen, C.; Bunupuradah, T.; Kerr, S.; Chuenyam, T.; Ubolyam, S.; Mahanontharit, A.; Suwanlerk, T.; Intasan, J.; Jupimai, T.; Intakan, P.; Hirunyanulux, T.; Pinklow, P.; Pruksakaew, K.; Butterworth, O.; Chomchey, N.; Sriheara, C 2012: Poor quality of life among untreated Thai and Cambodian children without severe HIV symptoms Aids Care 24(1): 30-38
Santamaria, J.; Tolosa, E.S.; Vallés, A.; Bayes, A.; Blesa, R.; Masana, J. 1987: Mental depression in untreated Parkinson's disease of recent onset Advances in Neurology 45: 443-446
Hu, X.Henry.; Bull, S.A.; Hunkeler, E.M.; Ming, E.; Lee, J.Y.; Fireman, B.; Markson, L.E. 2004: Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate Journal of Clinical Psychiatry 65(7): 959-965
Amin, M.M.; Ban, T.A.; Lehmann, H.E.; Khan, P. 1978: Viloxazine in the treatment of depression: psychophysical measures and clinical response Psychopharmacology Bulletin 14(1): 33-35
Brown, W.A.; Shrivastava, R.K.; Arato, M. 1987: Pre-treatment pituitary-adrenocortical status and placebo response in depression Psychopharmacology Bulletin 23(1): 155-159
Moore, F.D.; VanDevanter, S.B.; Boyden, C.M.; Lokich, J.; Wilson, R.E. 1974: Adrenalectomy with chemotherapy in the treatment of advanced breast cancer: objective and subjective response rates; duration and quality of life Surgery 76(3): 376-390
Ettigi, P.G.; Hayes, P.E.; Narasimhachari, N.; Hamer, R.M.; Goldberg, S.; Secord, G.J. 1983: D-Amphetamine response and dexamethasone suppression test as predictors of treatment outcome in unipolar depression Biological Psychiatry 18(4): 499-504
Jakovljević, M. 2014: The placebo-nocebo response in patients with depression: do we need to reconsider our treatment approach and clinical trial designs? Psychiatria Danubina 26(2): 92-95
Maes, M.; Mihaylova, I.; Leunis, J.-C. 2007: Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression Neuro Endocrinology Letters 28(6): 861-867
Rajewska-Rager, A.; Skibińska, M.; Szczepankiewicz, A.; Kapelski, Pł.; Dmitrzak-Weglarz, M.; Leszczyńska-Rodziewicz, A.; Hauser, J. 2008: Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression Psychiatria Polska 42(6): 915-923
Usman, M.; Syed, N.N.; Kakepoto, G.N.; Adil, S.N.; Khurshid, M. 2007: Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response Journal of the Association of Physicians of India 55: 103-107
Eschweiler, G.W.; Plewnia, C.; Batra, A.; Bartels, M. 2000: Does clinical response to repetitive prefrontal transcranial magnetic stimulation (r TMS) predict response to electroconvulsive therapy (ECT) in cases of major depression? Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 45(9): 845-846
Jarmuzewska, E.A.; Cerri, C.; Ghidoni, A.; Mangoni, A.A. 2003: High rate of neoplasia and other co-morbid conditions in type-2 diabetic patients with longer duration of disease and poor metabolic control Panminerva Medica 45(2): 133-143
Geiger, H.J. 1967: Of the poor, by the poor, or for the poor: the mental health implications of social control of poverty programs Psychiatric Research Reports 21: 55-65